XML 74 R36.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue (Tables) | 12 Months Ended
--- | ---
Apr. 25, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The table below illustrates net sales by segment and division and by market geography for fiscal years 2025, 2024, and 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.
| Worldwide
| Fiscal year
(in millions) | 2025 |  | 2024 |  | 2023
Cardiac Rhythm & Heart Failure | $ | 6,392 |  |  | $ | 5,995 |  |  | $ | 5,783 |
Structural Heart & Aortic | 3,554 |  |  | 3,358 |  |  | 3,363 |
Coronary & Peripheral Vascular | 2,535 |  |  | 2,478 |  |  | 2,375 |
Cardiovascular | 12,481 |  |  | 11,831 |  |  | 11,522 |
Cranial & Spinal Technologies | 4,973 |  |  | 4,756 |  |  | 4,451 |
Specialty Therapies | 2,940 |  |  | 2,905 |  |  | 2,815 |
Neuromodulation | 1,932 |  |  | 1,746 |  |  | 1,693 |
Neuroscience | 9,846 |  |  | 9,406 |  |  | 8,959 |
Surgical & Endoscopy | 6,498 |  |  | 6,508 |  |  | 6,152 |
Acute Care & Monitoring | 1,909 |  |  | 1,908 |  |  | 1,837 |
Medical Surgical | 8,407 |  |  | 8,417 |  |  | 7,989 |
Diabetes | 2,755 |  |  | 2,488 |  |  | 2,262 |
Reportable segment net sales | 33,489 |  |  | 32,142 |  |  | 30,731 |
Other operating segment(1) | 137 |  |  | 221 |  |  | 495 |
Other adjustments(2) | (90) |  |  | — |  |  | — |
Total net sales | $ | 33,537 |  |  | $ | 32,364 |  |  | $ | 31,227 |
| U.S. |  | International
| Fiscal year
(in millions) | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023
Cardiovascular | $ | 5,804 |  |  | $ | 5,597 |  |  | $ | 5,796 |  |  | $ | 6,677 |  |  | $ | 6,234 |  |  | $ | 5,725 |
Neuroscience | 6,713 |  |  | 6,305 |  |  | 6,018 |  |  | 3,133 |  |  | 3,101 |  |  | 2,941 |
Medical Surgical | 3,664 |  |  | 3,717 |  |  | 3,549 |  |  | 4,744 |  |  | 4,700 |  |  | 4,440 |
Diabetes | 923 |  |  | 852 |  |  | 849 |  |  | 1,832 |  |  | 1,636 |  |  | 1,413 |
Reportable segment net sales | 17,104 |  |  | 16,471 |  |  | 16,212 |  |  | 16,386 |  |  | 15,671 |  |  | 14,519 |
Other operating segment(1) | 68 |  |  | 91 |  |  | 160 |  |  | 70 |  |  | 131 |  |  | 335 |
Other adjustments(2) | — |  |  | — |  |  | — |  |  | (90) |  |  | — |  |  | — |
Total net sales | $ | 17,171 |  |  | $ | 16,562 |  |  | $ | 16,373 |  |  | $ | 16,365 |  |  | $ | 15,802 |  |  | $ | 14,854 |
(1)Includes operations and ongoing transition agreements from businesses the Company has exited or divested. (2)Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration